Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)
Status:
Completed
Trial end date:
2020-02-19
Target enrollment:
Participant gender:
Summary
This study aims to verify the hypothesis that patients with Vascular Ehlers Danlos syndrome
(vEDS) should benefit of the blockade of angiotensin (Ang) II noxious effects on their
vasculature affected by a defect in type III collagen in addition to the effects celiprolol.
This randomized, double blind, placebo controlled trial compares the administration of the
Ang II type I receptor blocker (ARB) - irbesartan- to placebo over a 2-year period in vEDS
patients with the main objective to reduce the incidence of both symptomatic and asymptomatic
vascular events.